Tech Company Financing Transactions

Exicure Funding Round

AbbVie Biotech Ventures and private investors invested in a Series B funding round for Exicure. The round was announced on 7/31/2013.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

8045 Lamon Ave. 410
Skokie, IL 60077
USA

Phone

(847) 673-1700

Website

www.exicuretx.com

Email Address

Not Recorded

Overview

AuraSense Therapeutics is a development-stage biotechnology company founded to pursue the unique commercial potential of Spherical Nucleic Acid (SNA) constructs. These novel constructs possess unparalleled biocompatibility and versatility as therapeutics.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Giljohann

        

Chief Financial Officer

David Snyder

        

Chief Operating Officer

Matthias Schroff

        

Browse more venture capital transactions:

Prev: 7/31/2013: ZestFinance venture capital transaction
Next: 7/31/2013: Trov venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary